In two women, everolimus was either undetectable or detectable in very small amounts in the colostrum. However, no information is available on the use of everolimus during breastfeeding. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. A woman was receiving everolimus 2 mg daily and cyclosporine 1.5 mg/kg daily during pregnancy and postpartum following a heart transplant. Although she did not breastfeed, a colostrum sample was obtained one day postpartum which contained undetectable everolimus levels (<0.5 mcg/L). The timing of the sample with respect to the previous everolimus dose was not stated. Measurement of serial plasma levels of everolimus obtained transplacentally found the estimated elimination half-life of everolimus to be about 86 hours in the newborn.[1]
A woman with a kidney transplant received azathioprine 125 mg, methylprednisolone 12 mg, and everolimus 0.5 mg daily during pregnancy and postpartum. On the second day postpartum, 6 colostrum samples were collected. The pre-dose level was 33 ng/L. The highest level was 66 ng/L at 4 hours after the dose. Samples taken at 2, 6, 8 and 12 hours after the dose contained concentrations that ranged from 45 to 51 ng/L.[2]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Fiocchi R, D'Elia E, Vittori C, et al. First report of a successful pregnancy in an everolimus-treated heart-transplanted patient: Neonatal disappearance of immunosuppressive drugs. Am J Transplant 2016;16:1319-22. [PubMed: 26555407]
2.
Kociszewska-Najman B, Szpotanska-Sikorska M, Mazanowska N, et al. Transfer of everolimus into colostrum of a kidney transplant mother. Ann Transplant 2017;22:755-8. [PMC free article: PMC6248263] [PubMed: 29255138]
Substance Identification
Substance Name
Everolimus
CAS Registry Number
159351-69-6
Drug Class
Breast Feeding
Lactation
Milk, Human
Immunosuppressive Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
